September 25, 2017 4:14 AM ET


Company Overview of Palatin Technologies, Inc.

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysf...

Cedar Brook Corporate Center

4B Cedar Brook Drive

Cranbury, NJ 08512

United States

Founded in 1986

22 Employees





Key Executives for Palatin Technologies, Inc.

Co-Founder, President, CEO & Director
Age: 55
Total Annual Compensation: $577.4K
Executive VP, CFO, COO, Treasurer & Secretary
Age: 60
Total Annual Compensation: $527.2K
Compensation as of Fiscal Year 2016.

Palatin Technologies, Inc. Key Developments

Palatin Technologies, Inc. Appoints Dr. Anthony M. Manning, Ph.D. to Board of Directors

Palatin Technologies, Inc. announced that Anthony M. Manning, Ph.D. was appointed to Palatin's Board of Directors on September 7, 2017. Dr. Manning currently serves as the Senior Vice President of Research at Momenta Pharmaceuticals, Inc, Cambridge, MA. Dr. Manning is responsible for research and the discovery of novel products as the Senior Vice President of Research at Momenta Pharmaceuticals, Inc. Since joining Momenta, his team has advanced three novel autoimmune drugs into development. Prior to Momenta, Dr. Manning was Vice President and Head of Immunology Research for Biogen Idec, Inc. Before that, he was Vice President and Global Head of Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals.

Palatin Technologies Announces Sign Licensing Agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Rights to Bremelanotide

Palatin Technologies, Inc. announced that it has entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. for exclusive rights to develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the territories of mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Bremelanotide is an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Under the terms of the agreement, Palatin will receive an upfront payment of $5.0 million and a $7.5 million milestone based on regulatory approval in China. Palatin has the potential to receive up to $92.5 million in sales related milestones and high single-digit to low double-digit royalties on net sales in the licensed territory. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territory will be the sole responsibility of Fosun Pharma.

Palatin Technologies, Inc. Presents at Rodman & Renshaw 19th Annual Global Investment Conference, Sep-12-2017 08:20 AM

Palatin Technologies, Inc. Presents at Rodman & Renshaw 19th Annual Global Investment Conference, Sep-12-2017 08:20 AM. Venue: Lotte New York Palace Hotel, 55 Madison Ave, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Palatin Technologies, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at